Zulma Bolena Lara Mayorga

Zulma Bolena Lara Mayorga

Auto-generated profile, based on publicly available information

Zulma Bolena Lara Mayorga

Renal Division, Macrotech Farmacéutica, Santo Domingo, Dominican Republic

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2026 in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
Verified
Journal Article
Closed access
SOSergio Óscar Hernández Ordóñez
Sergio Óscar Hernández Ordóñez
EEErwin Iván Campos Echavarría
Erwin Iván Campos Echavarría
EBElianny Sarina Polanco Brazoban
Elianny Sarina Polanco Brazoban
ZMZulma Bolena Lara Mayorga
Zulma Bolena Lara Mayorga
Miguel Angel Cuevas-BudhartMiguel Angel Cuevas-Budhart
Miguel Angel Cuevas-Budhart
ARAlfonso Ramos
Alfonso Ramos
Background: Chronic kidney disease (CKD) represents a growing public health challenge worldwide, particularly in countries with a medium sociodemographic index such as the Dominican Republic (DR), where both the incidence and prevalence of CKD have shown a sustained increase. In response, the DR government launched a national peritoneal dialysis (PD) program in 2013 to expand access to kidney replacement therapy (KRT). Methods: A retrospective analysis was conducted on the development and implementation of the national continuous ambulatory peritoneal dialysis (CAPD) program over ten years. The model was structured around three pillars: (1) a multidisciplinary team comprising nephrology, nursing, nutrition, psychology, and social work; (2) dedicated infrastructure for PD delivery; and (3) a management system driven by standardized processes and protocols, aligned with ISO certification standards. Patient care involved comprehensive baseline assessments, structured training, monthly follow-up, routine retraining, and home evaluations. Program performance was monitored through predefined clinical indicators. Results: Since the implementation of the program, the PD penetration in DR increased from 2.7% to 22.4%, reaching 1118 patients by the end of 2024. This growth reflects the program's ability to improve access to KRT through a centralized and standardized care model. This model not only facilitated consistency in care delivery across participating centers but also enhanced the growth of PD. Conclusions: The 10-year experience of the national PD program in the DR provides evidence for the feasibility and effectiveness of a standardized, patient-centered, and multidisciplinary PD program. The implementation of this program has significantly increased access to kidney replacement therapies and driven the sustained growth of KRT in the DR and provides a scalable model for the implementation of national PD initiatives in similar contexts.